Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRAINING Study
2024-519895-23-00Phase 3Authorised
- Sponsor
- Fundación Canaria de Investigación Sanitaria
- Start
- Jan 2025
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of antithymocyte globulin rabbit in kidney allograft rejection (2 arms), sponsored by Fundación Canaria de Investigación Sanitaria. Primary endpoint: Interstitial fibrosis and tubular atrophy (IF/TA) and graft renal function at 24 months. Planned start Jan 2025; status: authorised.
02
Drugs
antithymocyte globulin rabbit
03
Conditions
kidney allograft rejection
Beyond the preview
Go deeper on 2024-519895-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519895-23-00.